Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.60 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.32 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAPDH | P04406 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gs-441524 SCHEMBL31174011 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL15998246 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL10120689 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL22663744 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL24667691 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL10120691 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL23870459 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL22142944 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL24975226 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A | |
| Gs-441524 SCHEMBL28391751 | 1.00 | TMPRSS2 (0.60) | TMPRSS2CDK5CDK5R1POLRMTADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024096554-A1 | SUSTAINED-RELEASE PLGA MICROSPHERE CONTAINING GS-441524, AND METHOD FOR PRODUCING SAME | 충남대학교산학협력단 | 2024-05-10 | — | — | WO | disclosed |
| EP-3595672-B1 | COMPOUNDS FOR USE IN METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4088718-A1 | METHODS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20200376014-A1 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10682368-B2 | Methods of treating feline coronavirus infections | GILEAD SCIENCES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682368-B2 | Methods of treating feline coronavirus infections | SARS1, CPN1, CAT | TMPRSS2 62/4885CDK5 2267/4885CDK5R1 1597/4885 |
| US-20200376014-A1 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | CAT, ACE, ACE2 | TMPRSS2 9/4885CDK5 3317/4885CDK5R1 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.